Brief review on remdesivir

Venkata Niharika Daka; Lakshmi Sravanthi  Bandi; Sushma  Alla; Venkata Spandana Cheedella; Sadasiva Rao Galaba

doi:10.46795/ijhcbs.v2i3.222

Daka Venkata Niharika Pharm.D Intern, Department of Pharmacy Practice Hindu College of Pharmacy, Guntur, Andhra Pradesh-India
Bandi Lakshmi Sravanthi Pharm.D Intern, Department of Pharmacy Practice Hindu College of Pharmacy, Guntur, Andhra Pradesh-India
Alla Sushma Pharm.D Intern, Department of Pharmacy Practice Hindu College of Pharmacy, Guntur, Andhra Pradesh-India
Cheedella Venkata Spandana Pharm.D Intern, Department of Pharmacy Practice Hindu College of Pharmacy, Guntur, Andhra Pradesh-India
Sadasiva Rao Galaba Head of Department, department of Pharmacy Practice, Hindu College of Pharmacy, Guntur, Andhra Pradesh -India

DOI https://doi.org/10.46795/ijhcbs.v2i3.222

Abstract

Remdesivir is an investigational broad-spectrum small-molecule antiviral drug that has confirmed interest in the direction of RNA viruses in numerous families, which encompass Coronaviridae (alongside aspect SARS-CoV, MERS-CoV, and lines of bat coronaviruses able to infecting human respiratory epithelial cells), Paramyxoviridae (alongside aspect Nipah virus, respiratory syncytial virus, and Hendra virus), and Filoviridae (alongside aspect Ebola virus). Originally superior to cope with Ebola virus infection , remdesivir is a prodrug of the determine adenosine analog, each of which can be metabolized into an energetic nucleoside triphosphate (NTP) via the host. The determine nucleoside, GS-441524, has displayed antiviral interest within the direction of SARS-CoV, Marburg virus , and pussycat infectious peritonitis virus, amongst others. A fashion of research have tested the effects of these pills on coronaviruses (CoVs) each in vitro and in vivo the use of mouse and non-human primate animal models.

Keywords: Remedsivir, Covid-19, carboxylic ester, antiviral, SARS-CoV

Downloads

Download data is not yet available.

References

Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, Leist SR, Pyrc K, Feng JY, Trantcheva I, Bannister R, Park Y, Babusis D, Clarke MO, Mackman RL, Spahn JE, Palmiotti CA, Siegel D, Ray AS, Cihlar T, Jordan R, Denison MR, Baric RS. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017 Jun 28;9(396):eaal3653. doi: 10.1126/scitranslmed.aal3653. PMID: 28659436; PMCID: PMC5567817.

A.J. Brown, J.J. Won, R.L. Graham, K.H. Dinnon 3rd, A.C. Sims, J.Y. Feng, et al, Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase, Antivir. Res., 169 (2019), p. 104541,51016/j.antiviral.2019.104541.

M.L. Agostini, E.L. Andres, A.C. Sims, R.L. Graham, T.P. Sheahan, X. Lu, et al, Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease mBio, 9 (2) (2018), 10.1128/mBio.00221-18.

C.J. Gordon, E.P. Tchesnokov, J.Y. Feng, D.P. Porter, M. Gotte, The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus, J. Biol. Chem. (2020), 10.1074/jbc.AC120.013056.

https://www.gilead.com/news-and-press/press-room/press-releases/2020/4/gilead-announces-results-from-phase-3-trial-of-investigational-antiviral-remdesivir-in-patients-with-severe-covid-19 (accessed on 30/05/2020).

Goldman JD, Lye DCB et al. Remdesivir for 5 or 10 Days in Patients With Severe Covid-19. N Engl J Med. 2020 May 22.

Beigel JH, Tomashek KM et al. Remdesivir for the Treatment of Covid-19 — Preliminary Report. May 22, 2020, at NEJM.org.

Davies M, Osborne V, et al. Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment. Drug Saf. 2020 May 28. (accessed on 30/05/2020).

https://www.gilead.com/news-and-press/press-room/press-releases/2020/5/gilead-announces-approval-of-veklury-remdesivir-in japan for patients-with- severe covid 19(accessed on30/05/2020).

https://pubchem.ncbi.nlm.nih.gov/compound/Remdesivir.